Clinical Trials · NCT00870194
A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 255
- Start date
- Mar 2009
- Locations
- 36 sites, 7 countries
- Primary endpoint
- Change in HbA1c (Percent)